JP2014510067A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510067A5
JP2014510067A5 JP2013555797A JP2013555797A JP2014510067A5 JP 2014510067 A5 JP2014510067 A5 JP 2014510067A5 JP 2013555797 A JP2013555797 A JP 2013555797A JP 2013555797 A JP2013555797 A JP 2013555797A JP 2014510067 A5 JP2014510067 A5 JP 2014510067A5
Authority
JP
Japan
Prior art keywords
composition according
administration
pain
dosage form
tapentadol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013555797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/000905 external-priority patent/WO2012119728A1/en
Publication of JP2014510067A publication Critical patent/JP2014510067A/ja
Publication of JP2014510067A5 publication Critical patent/JP2014510067A5/ja
Pending legal-status Critical Current

Links

JP2013555797A 2011-03-04 2012-03-02 タペンタドールの非経口的投与 Pending JP2014510067A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449317P 2011-03-04 2011-03-04
US61/449,317 2011-03-04
EP11003602 2011-05-03
EP11003602.7 2011-05-03
PCT/EP2012/000905 WO2012119728A1 (en) 2011-03-04 2012-03-02 Parenteral administration of tapentadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017158324A Division JP6837944B2 (ja) 2011-03-04 2017-08-21 タペンタドールの非経口的投与

Publications (2)

Publication Number Publication Date
JP2014510067A JP2014510067A (ja) 2014-04-24
JP2014510067A5 true JP2014510067A5 (https=) 2016-08-25

Family

ID=44653043

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013555797A Pending JP2014510067A (ja) 2011-03-04 2012-03-02 タペンタドールの非経口的投与
JP2017158324A Expired - Fee Related JP6837944B2 (ja) 2011-03-04 2017-08-21 タペンタドールの非経口的投与
JP2021195330A Pending JP2022033863A (ja) 2011-03-04 2021-12-01 タペンタドールの非経口的投与
JP2023037505A Pending JP2023075244A (ja) 2011-03-04 2023-03-10 タペンタドールの非経口的投与

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017158324A Expired - Fee Related JP6837944B2 (ja) 2011-03-04 2017-08-21 タペンタドールの非経口的投与
JP2021195330A Pending JP2022033863A (ja) 2011-03-04 2021-12-01 タペンタドールの非経口的投与
JP2023037505A Pending JP2023075244A (ja) 2011-03-04 2023-03-10 タペンタドールの非経口的投与

Country Status (22)

Country Link
US (3) US20120225951A1 (https=)
EP (2) EP2680833B1 (https=)
JP (4) JP2014510067A (https=)
KR (2) KR101970468B1 (https=)
CN (2) CN103501775A (https=)
AU (2) AU2012224953C1 (https=)
BR (1) BR112013022213A2 (https=)
CA (1) CA2828635C (https=)
CY (1) CY1117426T1 (https=)
DK (1) DK2680833T3 (https=)
EA (2) EA024193B1 (https=)
ES (1) ES2573414T3 (https=)
HR (1) HRP20160400T1 (https=)
HU (1) HUE027514T2 (https=)
IL (1) IL227825A (https=)
MX (1) MX348831B (https=)
PL (1) PL2680833T3 (https=)
PT (1) PT2680833E (https=)
RS (1) RS54711B1 (https=)
SI (1) SI2680833T1 (https=)
WO (1) WO2012119728A1 (https=)
ZA (1) ZA201306479B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
MX388963B (es) 2011-03-04 2025-03-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral
EP3300726A1 (en) 2011-07-29 2018-04-04 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
WO2014068372A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
CN103735500B (zh) * 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
PE20171651A1 (es) * 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
US11090278B2 (en) * 2019-05-16 2021-08-17 Nexus Pharmaceuticals, Inc. Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
EP4011369A1 (en) * 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334422D0 (en) * 1983-12-23 1984-02-01 Sterwin Ag Composition
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
BR0110382A (pt) * 2000-04-27 2003-06-24 Pfizer Prod Inc Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos
EP1282416A2 (en) * 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
JP4905616B2 (ja) * 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040180915A1 (en) * 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2007065156A2 (en) * 2005-12-02 2007-06-07 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
PT1612203E (pt) * 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
EP1893190A4 (en) * 2005-04-28 2010-07-28 Theraquest Biosciences Llc METHODS AND COMPOSITIONS FOR TREATING PAIN
ATE502629T1 (de) 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
PL2012764T3 (pl) * 2006-04-28 2011-04-29 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylopropylo)fenol i Paracetamol
BRPI0714671B8 (pt) * 2006-07-24 2023-03-21 Janssen Pharmaceutica Nv Preparação de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina e compostos intermediários
EP1905440A1 (de) * 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) * 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
RS55769B1 (sr) 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
CN101961315B (zh) * 2010-09-10 2012-09-05 海南美兰史克制药有限公司 一种门冬氨酸鸟氨酸脂质体注射液

Similar Documents

Publication Publication Date Title
JP2014510067A5 (https=)
JP2013535422A5 (https=)
HRP20160400T1 (hr) Parenteralna primjena tapentadola
JP2016539921A5 (https=)
US20190358173A1 (en) Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
JP2021073187A (ja) 即効型インスリン組成物
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
AU2017283785A1 (en) Synergistic antifungal compositions and methods thereof
WO2017216722A2 (en) Synergistic antifungal compositions and methods thereof
JP2013534244A5 (https=)
RU2016119746A (ru) Стабильный состав инсулина глулизин
EP3581169A1 (en) Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US9155734B2 (en) Stability of hydromorphone hydrochloride solutions
ECSP17064188A (es) Formulación estable para administración parenteral de tapentadol
JP2019142972A5 (https=)
JPWO2017038872A1 (ja) 抗真菌活性を有する組成物
KR20200018438A (ko) 향상된 용해도의 약물-함유 제형
EP2338473A1 (en) Pharmaceutical dosage forms of tizanidine and administration routes thereof
CN104244925B (zh) 盐酸氢吗啡酮溶液的提高的稳定性
JP2019142972A (ja) タペンタドールの非経口的投与
US20170340647A1 (en) Preservative-free Treprostinil Formulations and Methods and Devices for Use with Same
CN103142512B (zh) 一种高品质的含有奥沙利铂的组合物及其制备方法
RU2019130436A (ru) Фармацевтическая композиция для буккального/десенного введения парацетамола
RU2633635C1 (ru) Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
Khandelwal et al. Health economic outcome analysis of patients randomized in the SECURE phase 3 trial comparing isavuconazole to voriconazole for primary treatment of invasive fungal disease caused by aspergillus species or other filamentous fungi